Thank you @DrDevikaA for highlighting our data showing successful implementation of incretin therapy in patients with CV disease.
With careful titration, we can achieve a low discontinuation rate similar to trials and much lower than prior real world data would suggest.
With careful titration, we can achieve a low discontinuation rate similar to trials and much lower than prior real world data would suggest.
sciencedirect.com/science/articl…View quoted post on X
Real-world data on incretin therapy prescribing from a cardiology-based cardiometabolic program
@txchapteracc @PSatishMD